1. Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 13 Leprostatic Drugs

2. Copyright © 2008 Lippincott Williams & Wilkins. Introduction Chronic, communicable disease;long incubation period AKA “Hansen’s disease”: Caused by the bacterium Mycobacterium Peripheral nerves affected & skin lesions that are painful Leprostatic drugs: Help to control the disease; prevent complications

3. Copyright © 2008 Lippincott Williams & Wilkins. Medications to Recognize Dapsone clofazimine (Lamprene) rifampin ( Rifadin) ethionamide (Trecator)

4. Copyright © 2008 Lippincott Williams & Wilkins. Clofazimine Actions and uses –Has anti-inflammatory action; bactericidal against M. leprae –Action: Binds with DNA of mycobacterium, causing cell death –Use: Primary combined leprosy therapy; inflammation of nodular disease

5. Copyright © 2008 Lippincott Williams & Wilkins. Dapsone Actions and uses –Used to treat: Leprosy Dermatitis herpetiformis Chronic and inflammatory skin disease –Effective in prophylactic treatment of Pneumocystis carinii pneumonia

6. Copyright © 2008 Lippincott Williams & Wilkins. Nursing Process: The Patient Receiving a Leprostatic Drug – Assessment Preadministration assessment –Perform complete physical examination and history before the initiation of therapy –Examine areas and describe them in detail on the patient's record for comparison during therapy

7. Copyright © 2008 Lippincott Williams & Wilkins. Nursing Process: The Patient Receiving a Leprostatic Drug – Assessment (cont’d) Ongoing assessment –Drugs often given on outpatient basis –Perform general physical examination at every visit Pay particular attention to affected areas

8. Copyright © 2008 Lippincott Williams & Wilkins. Nursing Process: The Patient Receiving a Leprostatic Drug – Evaluation Therapeutic drug effect achieved Patient –Has resources to deal with body image changes –Verbalizes understanding of treatment modalities and importance of follow-up care –Demonstrates understanding of drug regimen –Complies with prescribed drug regimen

9. Copyright © 2008 Lippincott Williams & Wilkins. End of Presentation